Abstract 4757
Background
In the U.S., most mCRPC patients will receive an ARSi (abiraterone, enzalutamide) in 1st line. More than 60% will receive a second, sequential ARSi (A-A) as opposed to ARSi then Taxane (A-T). No randomized studies exist comparing A-A and A-T. Recent real-world cohort risk-adjusted analyses were not able to discern differences in overall survival (OS) between A-A and A-T, despite a wide range of observed outcomes within groups. Using a cross-sectional cohort of standard of care in a tertiary center, we sought to determine if observations were consistent with community, and evaluate if nuclear AR-V7 could have additive effect on OS, specifically post-ARSi failure.
Methods
We previously reported utility of nuclear AR-V7 in two cross-sectional cohorts (Scher et al 2016 and Scher et al 2018). Blood was drawn from mCRPC patients prior to new line of therapy, AR-V7 testing by Epic Sciences, and therapy choice by physician without knowledge of AR-V7 status. OS data was updated, and a subset of these combined cohorts were analyzed (n = 148): those who had failed an ARSi, and were about to go onto a second ARSi (n = 73) or taxane (n = 75). A risk score was used to adjust for underlying patient imbalances and therapy choice propensity.
Results
75 of 148 (51%) received A-T and 73 of 148 (49%) received A-A. Adjusting for patient risk, a discernable difference in OS was not detected (HR: 1.16, CI: 0.73 – 1.85, p = 0.52). Incorporating AR-V7, there was a significant interaction between positivity for AR-V7 and OS on taxanes (HR: 0.16, CI: 0.052 – 0.52, p = 0.0020). In risk-matched analysis, there was a significant difference in OS between AR-V7(+) patients on taxanes vs. ARSi (11.6mo vs. 5.5mo, p = 0.0029).
Conclusions
Sequential ARSi use in the U.S. is common. Adjusting for patient risk and physician therapy choice, AR-V7 use after ARSi failure identifies patients who would live longer on taxanes vs. ARSi. Physician intuition alone was not sufficient to achieve predictive effect of AR-V7.
Clinical trial identification
Legal entity responsible for the study
MSKCC.
Funding
NIH/NCI P50-CA92629 SPORE in Prostate Cancer, NIH/NCI Cancer Center Support Grant P30-CA008748, NIH grant R01-CA207220, Department of Defense Prostate Cancer Research Program (PC121111 and PC131984), Prostate Cancer Foundation Challenge Award, and David H. Koch Fund for Prostate Cancer Research.
Editorial Acknowledgement
Disclosure
H.I. Scher: Consultant: Sanofi, Clovis, Janssen, Pfizer; Grant/research support to MSK: Innocrin, Janssen; Board of directors: Asterias Biotheraputics; Advisory board: WCG Oncology. R.P. Graf: Employee: Epic Sciences, Inc. R. Dittamore: Employee of Epic Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract